Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.60 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744502 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL29744560 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL29744620 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL19972761 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL19981960 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL29744552 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL19972736 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL21294359 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL21294402 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 | |
| SCHEMBL29744556 | 1.00 | KCNH2 (0.60) | KCNH2OPRM1OPRD1OPRK1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109790125-B | Tetrahydroisoquinoline kappa opioid antagonists | 研究三角协会 | 2022-07-05 | — | — | CN | claimed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | claimed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | claimed |
| CN-109790125-B | Tetrahydroisoquinoline kappa opioid antagonists | 研究三角协会 | 2022-07-05 | — | — | CN | disclosed |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | KCNH2 589/4885OPRM1 3/4885OPRD1 2/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | KCNH2 633/4885OPRM1 3/4885OPRD1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.